Elco Management Co., LLC Lineage Cell Therapeutics, Inc. Transaction History
Elco Management Co., LLC
- $186 Million
- Q4 2024
A detailed history of Elco Management Co., LLC transactions in Lineage Cell Therapeutics, Inc. stock. As of the latest transaction made, Elco Management Co., LLC holds 14,900 shares of LCTX stock, worth $10,132. This represents 0.0% of its overall portfolio holdings.
Number of Shares
14,900
Previous 12,000
24.17%
Holding current value
$10,132
Previous $10,000
30.0%
% of portfolio
0.0%
Previous 0.01%
Shares
3 transactions
Others Institutions Holding LCTX
# of Institutions
134Shares Held
106MCall Options Held
22.1KPut Options Held
0-
Broadwood Capital Inc New York, NY41.7MShares$28.3 Million1.65% of portfolio
-
Black Rock Inc. New York, NY9.56MShares$6.5 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.63MShares$5.87 Million0.0% of portfolio
-
Perceptive Advisors LLC New York, NY7.24MShares$4.92 Million0.12% of portfolio
-
Defender Capital, Llc.5.96MShares$4.06 Million1.17% of portfolio
About Lineage Cell Therapeutics, Inc.
- Ticker LCTX
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 169,755,008
- Market Cap $115M
- Description
- Lineage Cell Therapeutics, Inc., a clinical-stage biotechnology company, develops novel cell therapies for the treatment of degenerative diseases in the United States and internationally. The company develops OpRegen, a retinal pigment epithelium cell replacement therapy, which is in Phase I/IIa clinical trial for the treatment of the dry age-re...